TXR-712

TXR-712 is an investigational **small-molecule** drug candidate discovered by twoXAR Pharmaceuticals, now Aria Pharmaceuticals, for the treatment of **systemic lupus erythematosus**. Publicly available information indicates that TXR-712 emerged from an AI-enabled discovery program and showed **preclinical efficacy and tolerability** in murine lupus models, including improvements in renal inflammation and kidney function markers such as blood urea nitrogen and proteinuria. The specific **molecular target and mechanism of action have not been publicly disclosed**, although company and conference materials describe it as having a **novel mechanism of action** distinct from standard lupus therapies. The program appears to remain at the **preclinical** stage.